FiercePharma

MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug

AstraZeneca's ($AZN) MedImmune has licensed a toll-like receptor (TLR) agonist from 3M ($MMM), in the hopes that intratumoral injection of the candidate will allow ...